Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




Dec
03
Today In Oncology
Addition of Neoadjuvant LuPSMA PNT2002 to SBRT in Oligorecurrent Prostate Cancer
Preliminary Activity of LuPSMA-IT Plus Ra-223 in Metastatic Castration-Resistant Prostate Cancer With Bone Metastasis
Image-Only AI Model Outperforms Breast Density for 5-Year Breast Cancer Risk Stratification
Tisagenlecleucel in Relapsed or Refractory Large B-Cell Lymphoma
Retrospective Review Shows Persistent Breast Cancer Burden in Younger Women
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo